Oncolytics reports ~15-month response duration in anal cancer

Oncolytics Biotech reported approximately 15-month median response duration for pelareorep plus atezolizumab in second-line or later anal cancer, surpassing the historical 9.5-month benchmark. Following FDA Fast Track Designation, the company aims to pursue additional studies and an accelerated approval pathway, subject to FDA agreement.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.